#CLLS

Cellectis Announces 2026 Strategy and Catalysts Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key

2 months ago

#CLLS Cellectis Announces 2026 Strategy and Catalysts

www.stocktitan.net/news/CLLS/cellectis-anno...

0 0 0 0

Trade Alerts, Monday December 16, 2025 – Crystal Equity Research

2 months ago

Small-cap stocks gapping down in trading, Tue Dec 16th - #VBIX #SVRE #DXST #CVKD #ZYXI #LWLG #IRBT #DFLI #CLLS #AKTX - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Cellectis Announces Arbitral Decision in Dispute with Servier Cellectis (NASDAQ: CLLS) announced an Arbitral Tribunal decision dated December 15, 2025 in its arbitration with Les Laboratoires Servier and IRIS SARL relating to the March 6, 2019 License Agreement.The Tribunal ordered a partial termination of the License Agreement with respect to product UCART19 V1 (also called ALLO-501) and provided that Cellectis shall, at Allogene’s request, engage in good-faith discussions about granting a direct license to UCART19 V1. All other claims between the parties were dismissed.

2 months ago

#CLLS Cellectis Announces Arbitral Decision in Dispute with Servier

www.stocktitan.net/news/CLLS/cellectis-anno...

0 0 0 0

@jyves94.bsky.social

3 months ago

À mon avis, #CLLS est un excellent « achat » spéculatif basé sur son potentiel clinique avec lasme-cel, une valorisation bas et des partenariats R&D.

1 0 0 0

@jyves94.bsky.social

3 months ago

Le potentiel allogène de la #CAR_T 🧬 de #Cellectis 🚀 justifie toujours un « achat »

🚀 #CLLS développe des #CAR_Tcells 🧬 éditées par #TALEN ✂️ en standard

Son principal actif interne est lasme-cel pour r/r B-#LLA 🩸 et eti-cel pour r/r B-cell #NHL

seekingalpha.com/article/4852...

1 0 1 0

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL Cellectis (NASDAQ:CLLS) presented updated Phase 1 NATHALI-01 data for eti-cel, an allogeneic dual CD20/CD22 CAR-T for relapsed/refractory non-Hodgkin lymphoma (r/r NHL).At the current dose level, eti-cel showed an 88% overall response rate (ORR) and 63% complete response (CR) in n=8 patients. In vivo data suggested that low-dose interleukin-2 (IL-2) support may enhance CAR-T expansion and persistence without increasing toxicity. Cellectis will begin enrollment in an IL-2 support cohort in Q1 2026 and expects to present the full Phase 1 dataset in 2026. The poster will be posted on the company website.

3 months ago

#CLLS ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

www.stocktitan.net/news/CLLS/ash-2025-celle...

0 0 0 0

Monthly information on share capital and company voting rights Cellectis (CLLS) published its monthly information on share capital and voting rights as of November 30, 2025. The release reports the total number of shares as 100,325,454 and the total number of voting rights as 105,406,812. The announcement lists the listing market as Euronext Growth and the ISIN code as FR0010425595. Contact details for media and investor relations are provided for further information.

3 months ago

#CLLS Monthly information on share capital and company voting rights

www.stocktitan.net/news/CLLS/monthly-inform...

0 0 0 0

Trade Alerts, Monday November 24, 2025 – Crystal Equity Research

3 months ago

Small-cap stocks gapping up in trading, Mon Nov 24th - #YDES #HSAI #VOR #SLRX #NXTC #MXL #ENLV #CLLS #BLFY #AEHL #MAGN #GNK #CMDB #BFLY - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells Cellectis (NASDAQ: CLLS) published a Nature Communications article on Nov 19, 2025 describing a non-viral gene insertion process using circular single-stranded DNA (CssDNA) donor templates combined with TALEN gene editing in hematopoietic stem and progenitor cells (HSPCs).Key results: CssDNA produced 3–5x higher knock-in efficiency than linear ssDNA with efficiencies surpassing 40%; CssDNA enabled insertion at multiple HSPC loci and worked in primary T cells; CssDNA-edited HSPCs showed higher engraftment and maintenance of edits in a murine model versus AAV6-edited HSPCs.This work positions CssDNA as an efficient non-viral strategy to expand durable gene and cell therapy options.

3 months ago

#CLLS Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

www.stocktitan.net/news/CLLS/cellectis-publ...

0 0 0 0

@jyves94.bsky.social

4 months ago

Barclays réaffirme sa note d’achat sur #Cellectis ( #CLLS)

Dans un rapport, Gena Wang de #Barclays a maintenu une note d’achat sur Cellectis avec un objectif de cours de 8 $

Selon #TipRanks, Wang est un analyste 4 ⭐️⭐️⭐️⭐️ avec un taux de réussite de 44 %

www.tipranks.com/news/blurbs/...

1 0 0 0

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) Median OS of 14.8

4 months ago

#CLLS Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CLLS/cellectis-repo...

0 0 0 0

Monthly information on share capital and company voting rights Cellectis (Euronext Growth: CLLS) published its monthly report on share capital and voting rights as of Oct 31, 2025.Key figures: Total number of shares = 100,325,454; Total number of voting rights = 89,406,760. The disclosure follows Article 223-16 of the French financial markets authority general regulation and lists investor and media contact details for further information.

4 months ago

#CLLS Monthly information on share capital and company voting rights

www.stocktitan.net/news/CLLS/monthly-inform...

0 0 0 0

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL ○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative

4 months ago

#CLLS Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

www.stocktitan.net/news/CLLS/cellectis-r-d-...

0 0 0 0

Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers Cellectis (NASDAQ: CLLS) is hosting an R&D Day in New York City on October 16, 2025 to present pipeline progress for its allogeneic cell therapy program.Leadership and key opinion leaders will present the complete Phase 1 dataset and outline the pivotal Phase 2 trial design and commercial opportunity for lasme-cel (UCART22) in relapsed/refractory B‑ALL. The event runs 08:30–10:30 a.m. ET, is in-person and live via webcast, and a replay will be posted on the company website.

4 months ago

#CLLS Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

www.stocktitan.net/news/CLLS/cellectis-host...

0 0 0 0

Trade Alerts, Wednesday October 1, 2025 – Crystal Equity Research

5 months ago

Small-cap stocks gapping up in trading Wed Oct 1st - #PALI #NVA #GLXG #VTYX #RVYL #LGHL #CLLS #LAC - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Trade Alerts, Monday September 29, 2025 – Crystal Equity Research

5 months ago

Small-cap stocks gapping down in trading Mon Sept 29th - #YAAS #MTEK #JZXN #QSI #LRMR #KALA #IOBT #CLLS #BYND - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

5 months ago

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - bioAffinity Technologies (NASDAQ:BIAF), Avalo Therapeutics (NASDAQ:AVTX) Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket Shares of Merus NV (NASDAQ: MRUS ) rose sharply in today's pre-market trading . Genmab announced plans to acquire...

#AVTX #BIAF #CGC #CLLS #CYCU #ENTA #ENTA #EPOW #JFB #LRMR #MLTX

Origin | Interest | Match

0 0 0 0

100.3 Million Shares: Cellectis Biotech Reports Updated Capital Structure and Voting Rights for August 2025 French biotech Cellectis (CLLS) discloses 100,325,229 total shares and 89,428,230 voting rights as of August 31, 2025. Monthly regulatory update per Article 223-16.

6 months ago

#CLLS Monthly information on share capital and company voting rights

www.stocktitan.net/news/CLLS/monthly-inform...

0 0 0 0

Cellectis Reveals New Share Structure: 100.3M Shares, 89.4M Voting Rights in Latest Filing Latest Cellectis capital structure update shows 100.3M shares and 89.4M voting rights. Get detailed breakdown of the biotech's latest shareholder metrics.

7 months ago

#CLLS Monthly information on share capital and company voting rights

www.stocktitan.net/news/CLLS/monthly-inform...

0 0 0 0

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates Cellectis (NASDAQ:CLLS) reported Q2 2025 financial results and significant pipeline developments. The company's cash position stands at $230 million, providing runway into H2 2027. Key developments include the completion of end-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL, with pivotal Phase 2 launch planned for H2 2025. Financial highlights show consolidated revenues of $30.2 million for H1 2025, up from $16.0 million in H1 2024, primarily driven by a $20.0 million increase in AstraZeneca collaboration revenue. The company reported a net loss of $41.9 million ($0.42 per share) compared to $19.6 million ($0.24 per share) in the same period last year. Pipeline progress includes ongoing Phase 1 study of eti-cel (UCART20x22) in r/r NHL with readout expected in late 2025, and advancement of three programs under the AstraZeneca partnership. A Servier arbitration decision is expected by December 15, 2025.

7 months ago

#CLLS Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

www.stocktitan.net/news/CLLS/cellectis-repo...

0 0 0 0

Evening Forest News

@forrestnews.bsky.social

8 months ago

Happy Bastille Day! #clls

1 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

8 months ago

Small-cap stocks with improving money flow, Thu Jul 10th - #PXLW #AMTD #KMT #NEGG #LPG #MIST #TRC #HELE #VNCE #CLLS #WTTR #ADTN #QTTB #RMNI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Cellectis Reports 100.3M Total Shares: Latest Capital Structure and Voting Rights Revealed Latest Cellectis regulatory filing reveals updated share capital structure and voting rights distribution. See detailed breakdown of shareholder voting power.

8 months ago

#CLLS Monthly information on share capital and company voting rights

www.stocktitan.net/news/CLLS/monthly-inform...

0 0 0 0

Biotech Leader Strengthens Board: Idorsia CEO André Muller Joins Cellectis as Strategic Advisor Idorsia Pharmaceuticals CEO André Muller brings extensive biotech leadership experience to Cellectis board. Two directors step down as company reshapes governance. Learn more.

8 months ago

#CLLS Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025

www.stocktitan.net/news/CLLS/cellectis-repo...

0 0 0 0

Cellectis Share Capital Reaches 100.3M Shares: Latest Voting Rights and Capital Structure Revealed Just released: Cellectis reports 89.1M voting rights from 100.3M total shares. See complete shareholding structure and latest capital distribution details.

9 months ago

#CLLS Monthly information on share capital and company voting rights

www.stocktitan.net/news/CLLS/monthly-inform...

0 0 1 0

Cellectis Reports Financial Results for the First Quarter 2025 Cellectis (NASDAQ: CLLS) reported Q1 2025 financial results and provided pipeline updates. The company reported a cash position of $246 million as of March 31, 2025, providing runway into H2 2027. Key pipeline developments include expected Phase 1 data for lasme-cel (UCART22) in Q3 2025 and eti-cel (UCART20x22) readout in late 2025. The company's partnership with AstraZeneca continues with ongoing R&D activities in three programs. Financial highlights include: - Revenue increased to $12.0 million vs $6.5 million in Q1 2024 - R&D expenses decreased to $21.9 million from $22.3 million - Net loss of $18.1 million ($0.18 per share) compared to net income of $5.6 million in Q1 2024 - Cash burn of $18 million during Q1 2025

10 months ago

#CLLS Cellectis Reports Financial Results for the First Quarter 2025

www.stocktitan.net/news/CLLS/cellectis-repo...

0 0 0 0

Monthly information on share capital and company voting rights Cellectis (CLLS) has released its monthly share capital and voting rights report as of April 30, 2025. The company reported a total of 100,290,220 shares in its capital structure, with 89,075,490 total voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth.

10 months ago

#CLLS Monthly information on share capital and company voting rights

www.stocktitan.net/news/CLLS/monthly-inform...

0 0 0 0

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils research data on TALEN®-mediated

10 months ago

#CLLS Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

www.stocktitan.net/news/CLLS/cellectis-pres...

0 0 0 0